Survey: Pharma Commercial Teams Want More Data Analytics Solutions

2024-03-24
The commercial teams of pharmaceutical companies are looking for more data analytics and business insights and they’re willing to spend more money to do it. Those are some of the findings of a recent survey of pharma industry executives at U.S.-based companies. The survey was conducted by independent survey company Global Surveyez, but it was commissioned by Verix, a Santa Clara, California-based company that provides an AI-based technology platform that supports life sciences commercial operations. In other words, it has a financial interest in the topics covered by the survey. Verix competitors that also offer analytics solutions for pharmaceutical commercialization include Whiz.AI, Axtria, and ngram. According to the survey results reported earlier this month, 76% of respondents turn to consulting agencies for business insights and data analytics, beating technology vendors at 58% and data consolidators at 32%. Just 21% of survey respondents use in-house solutions. The top challenge for pharma companies is lack of automation, making it difficult to extract timely and accurate insights, a problem cited by 74% of respondents. Pain points—a different question than top challenges—included increasing brand share, effectively allocating resources across brands, and targeting the right healthcare providers. However, the pain point responses were fairly evenly spread across with no single one standing out. Given the pain points responses, it’s probably not a surprise that 79% of respondents agreed that accurate insights would positively impact brand performance. Survey respondents expressed interest in artificial intelligence-driven data analytics solutions. Results show 69% of commercial teams are increasing their budgets in this area versus 5% of respondents who said they are reducing this spending. The Verix survey was conducted in the fourth quarter of last year. The Verix survey and report includes responses from 100 senior-level pharma industry executives spread equally across sales, marketing, and brand. The companies represented in the survey have annual revenue of at least $100 million. Here’s a link to the survey and report.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
-
靶点
-
药物
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。